This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
Delivered as Hybrid Event from 15-18 November 2022
Live In-Person Conference Delivered 15-18 NovemberAustria Center Vienna

Shuhao Zhu
Co Founder & Chief Scientific Officer at Guardian Therapeutics


Shuhao Zhu, PhD, has more than 20 years of industry experience in Discovery sciences in multiple therapeutic areas including Oncology, Autoimmune, Infectious Diseases, and Cardiovascular. He has been working to advance aptamer technology since 2005. In 2013, Shuhao co-founded Band Therapeutic based upon the discovery of BT200 and was responsible for the preclinical development of BT200. Band Therapeutics was acquired by Guardian Therapeutics in 2018 and he has since been the CSO of Guardian.

Agenda Sessions

  • Chairperson’s Remarks

  • BT200, A Novel von Willebrand Factor (vWF) Binding Aptamer for Bleeding Disorders